News und Analysen
IRIS2 lifts off as European Commission and SpaceRISE sign contract in Brussels
SpaceRISE, the consortium comprising Eutelsat, Hispasat and SES, has signed the agreement with the European Commission (EC) and the European Space Agency (ESA) that will see the consortium design
Prediction: After Crushing the Market in 2024, United Rentals Could Have Another Winning Year in 2025
Investors don't need to just invest in flashy companies that make the headlines to beat the market. Names like Nvidia and Tesla may be exciting to follow, but a quiet, industrial stock like United
Is Applied Materials Stock a Buy Now?
Applied Materials (NASDAQ: AMAT), one of the world's largest suppliers of semiconductor manufacturing equipment, has been a great long-term investment. Over the past 10 years, its stock rallied more
The $1 Trillion Ad Opportunity
In this podcast, Motley Fool analyst David Meier and host Dylan Lewis discuss:
Then Motley Fool analyst Asit Sharma joins host Mary Long for a look at LVMH's Bernard Arnault and what he has in
FIGEAC AÉRO: 2025/26 HALF-YEAR RESULTS: A SOLID PERFORMANCE, IN LINE WITH FULL-YEAR TARGETS
Verimatrix: Unterzeichnung einer Vereinbarung über den Verkauf von XTD-Vermögenswerten (Code- und Anwendungsschutz) an Guardsquare
Verimatrix (Euronext Paris: VMX (FR0010291245), ein führender Anbieter von Benutzersicherheitslösungen für eine sicherere vernetzte Welt, gibt die Unterzeichnung einer Vereinbarung mit dem
Verimatrix: Signing of an Agreement for the Sale of XTD Assets (Code and Application Protection) to Guardsquare
Regulatory News:
VERIMATRIX (Euronext Paris: VMX, FR0010291245), a leading provider of user security solutions for a safer connected world, announces the signing of an agreement with
Sensorion Reports Independent Data Monitoring Committee Raises No Safety Concerns and Agrees to Continue SENS-501’s Audiogene Phase 1/2 Trial
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
Correction of a release from 04.12.2025 17:56 CET/CEST - BILENDI: Proprietary Market Research Panels in 44 Countries, Supported by the Highest Quality Standards
BILENDI: Proprietary Market Research Panels in 44 Countries, Supported by the Highest Quality Standards
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
ABIONYX Pharma and SEBIA Announce an Exclusive Global Strategic Partnership to Transform Sepsis Diagnosis
Regulatory News:
ABIONYX Pharma, (FR0012616852 – ABNX – eligible PEA PME), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its
ABIONYX Pharma Enters Advanced Strategic Discussions with IHU SEPSIS, the World’s First Center Dedicated to Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX), a next-generation biotechnology company developing breakthrough therapies for severe and underserved diseases, today announced it has entered advanced
FIGEAC AÉRO: H1 2025/26 REVENUE €215.3 MILLION, IMPLYING 9.6% ORGANIC GROWTH 18th CONSECUTIVE QUARTER OF GROWTH IN LINE WITH THE FULL-YEAR TARGET
BILENDI: 2025 revenue as of 30 September: €64.5 million, up +42.9%
EQS-News: Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
ROCTOOL: Postponement of publication of 2025 half-year results
Prodware: Phast Invest announces its intention to file a public buy-out offer, followed by a squeeze-out for Prodware shares at €28 per share
ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the world's only recombinant apoA-I, today announced the publication of a ground breaking
Correction of a release from 20.10.2025 17:55 CET/CEST - Freelance.com: Results for the first half of 2025
Prodware: Upward trend in results during the first half of 2025
Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2025
PATRIMOINE ET COMMERCE: Q3 2025 RESULTS +9.5% IN GROSS RENTAL INCOME AT €43.3M